The potential benefits of anti-Tim3 inhibitors for gastric cancer patients and their potential for use in combination with anti-PD-1/PD-L1 inhibitors in the treatment of gastric cancer need further research. This evidence concerns the gene HAVCR2 and gastric cancer.